02.11.11
The Danish Council for Strategic Research has granted more than $3 million for a research project that will investigate the use of resveratrol for management of metabolic syndrome, osteoporosis and inflammation in humans. Fluxome A/S will supply Fluxome Resveratrol for the trials.
The 5-year project starts in June 2011 and participants will consume resveratrol for 12 months. The objective of the project is to determine if resveratrol can neutralize the detrimental effect of obesity on the whole body metabolism such as low-grade chronic inflammation, insulin resistance and lipid infiltration/inflammation in liver and skeletal muscle. For further information: www.fluxome.com
The 5-year project starts in June 2011 and participants will consume resveratrol for 12 months. The objective of the project is to determine if resveratrol can neutralize the detrimental effect of obesity on the whole body metabolism such as low-grade chronic inflammation, insulin resistance and lipid infiltration/inflammation in liver and skeletal muscle. For further information: www.fluxome.com